
BIOA Stock Forecast & Price Target
BIOA Analyst Ratings
Bulls say
Bioage Labs is well-positioned for future success with a strong financial runway through 2029 and a promising pipeline of clinical product candidates targeting molecular causes of aging. Their innovative approach to addressing metabolic diseases by targeting inflammation and the aging process sets them apart from traditional biopharmaceutical companies. The recent announcement of the dosing of the first participant in their QUELL-DME trial is a significant milestone and demonstrates the potential of their NLRP3 inhibitor BGE-102 to improve vision and reduce inflammation. The company's partnership with Lilly and their focus on developing treatments for conditions driven by inflammation further solidifies their potential for success in the industry.
Bears say
Bioage Labs is a clinical-stage biopharmaceutical company developing therapeutic products for metabolic diseases by targeting the biology of human aging. Despite the company's differentiated human datasets and technology platform, the high-stake demanding comparisons and long timelines for potential approvals may lead to financial challenges and delays in bringing their products to market. With a current valuation of around $336 million and a $25 price target, risks for investors include unexpected clinical outcomes, regulatory uncertainty, and a complex and price-sensitive commercial market.
This aggregate rating is based on analysts' research of BioAge Labs Inc. and is not a guaranteed prediction by Public.com or investment advice.
BIOA Analyst Forecast & Price Prediction
Start investing in BIOA
Order type
Buy in
Order amount
Est. shares
0 shares